CD274 and non-small cell lung carcinoma: Early immunotherapy studies in non-small-cell lung cancer evaluated the efficacy of PD-L1 single-agent blockade therapy in previously treated advanced NSCLC and showed greater effectiveness than standard docetaxel chemotherapy.